Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes.

ABSTRACT: Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention.

SUBMITTER: Khan MS 

PROVIDER: S-EPMC6848945 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature